United European Gastroenterology

.

Hello everyone, I'm Remo Panaccione, Professor of Medicine and Director of the Inflammatory Bowel Disease Clinic at the University of Calgary.

I was very happy that I just chaired a symposium here in beautiful Barcelona during UEGW week.

And so during that symposium, we discussed different patients and where possibly JAK inhibitors fit in the management of inflammatory bowel disease.

And there were some messages that were very clear on where these drugs should fit.

Certainly in Canada, we do use them first line.

In other jurisdictions, you need to use biosimilar anti-TNF, but this is a drug that you should consider certainly after an anti-TNF failure if you're in that position in your own country.

Now, I'm going to transition to maybe speaking about where do IL-23 inhibitors fit and what is some of the new data? So one of the most exciting things here at UEGW is the study, the AFIRM study.

I'm a gastroenterologist and professor in GI oncology at the Amsterdam University Medical Centers.

I just chaired a session here in Barcelona at UEG Week, and that session was on the new guideline development on colorectal cancer screening.

And I think it was a very nice and interesting session because we had somebody from the EU explain the whole process for all the cancer screening programs, which is not just colorectal cancer.

So there's a larger plan on how to organize that.

the show name Mazel D.

So we are here at UEG, United European Gastroenterology Congress, and it was a surprise for me that we have seen many lectures related to liver disease.

So this means that gastroenterologists are also opening to an unrecognized disease also in our digestive disease clinics.

And what we are seeing is that with screening pathways and referral pathways, we are diagnosing patients with this disease and identifying those ones that need treatment.

Perhaps you know it's a lovely ancient city that is known because it's the end of the way.

I'm so happy to be here in the UEG in order to share with the gastroenterology community What we have done today, I've been the chair in the symposium about the use of guselcumab in UC, and I think that will be amazing, speaking about all this new data that is IL-23, it's true that it's a mechanical faction that I've been using in recent years, and we have observed that it's a very new mechanical faction, for patients, for example, that have failed TTNF.

Why? Because in that subgroup of patients, it has been shown that they have very good results, but also in Bionave patients.

One of the strengths of this drug, I think that is that they have a double induction regimen.

My name is Jean-Frederic Lombard.

I'm the director of IBD Center at Icahn School of, uh, Medicine in New York.

And, uh, I'm here to discuss about the study that was presented during the UEGW, which is a verdict study.

So, uh, let's start by some words of, uh, introduction.

So the verdict study was, uh, conducted with, uh, a drug that you know all very well, which is vedolizumab, which is an alpha four, uh, beta seven anti-integrin.